|
Vorinostat Clinical Trials
4 actively recruiting trials across 4 locations
Also known as: L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid +2 more
Pipeline
Phase 1: 1Phase 2: 2Phase 1/2: 1
Top Sponsors
- Tanja Andrea Gruber1
- Medical College of Wisconsin1
- Giselle Sholler1
- Fred Hutchinson Cancer Center1
Indications
- Cancer4
- Lymphoblastic Leukemia1
- Acute Myeloid Leukemia, in Relapse1
- Castration-Resistant Prostate Carcinoma1
- Neuroblastoma1
Birmingham, Alabama1 trial
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
University of Alabama/Children's of Alabama
Phase 2
Phoenix, Arizona1 trial
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Phoenix Children's Hospital
Phase 1/2
Seattle, Washington1 trial
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Milwaukee, Wisconsin1 trial
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Children's Wisconsin
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.